Domain Therapeutics NA Inc. was founded as the North American subsidiary of Domain Therapeutics SA (Strasbourg, France).

Domain Therapeutics NA’s activities focus on leveraging Domain’s bioSensAll technology through:

  1. Research collaborations on the discovery of therapeutics with unique signaling signature with pharma/biotech partners.
  2. R&D efforts aimed at improving and expanding the bioSensAll technology.

In December 2013, Domain Therapeutics SA in-licensed the first generation of bioSensAll platform biosensors. These biosensors were initially developed with funding from the Quebec Consortium for Drug Discovery (CQDM), whose mission is to fund breakthrough technologies with the financial support of major pharma companies. This project was overseen by a team of researchers from various Quebec universities (Dr. Graciela Pineyro and Dr. Christian Le Gouill from the University of Montreal; Dr. Terry Hebert and Dr. Stéphane Laporte from McGill University; Dr. Richard Leduc from Sherbrooke University) and led by Dr. Michel Bouvier from the University of Montreal’s Institute for Research in Immunology and Cancer (IRIC).


Following its founding in 2014, Domain Therapeutics NA immediately signed its first service agreement. By the end of 2016, the company entered its 50th service contract. During this time, Domain Therapeutics NA was also granted federal funding from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). This funding contributed to the development of a novel generation of more powerful biosensors, which were subsequently in-licensed by Domain Therapeutics SA. Shortly thereafter, a non-exclusive sublicense of the bioSensAll™ platform was granted to Alkermes Inc.

“Domain Therapeutics; a dedicated partner to novel drug discovery and early development endeavours.”